The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil

AIDS

Volumn 21, Issue 11, 2007, Pages 1441-1448

  Golub, Jonathan E ^a   Saraceni, Valeria ^b   Cavalcante, Solange C ^b,c,d   Pacheco, Antonio G ^b,c,d   Moulton, Lawrence H ^a   King, Bonnie S ^a   Efron, Anne ^a   Moore, Richard D ^a   Chaisson, Richard E ^a,e   Durovni, Betina ^b,c,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Municipal Health Secretariat   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e Center for Tuberculosis Research   (United States)

Author keywords

Antiretroviral therapy; Brazil; HIV; Isoniazid; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID;

ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL RECORD REVIEW; MONOTHERAPY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; RISK REDUCTION; TUBERCULOSIS;

ADULT; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; BRAZIL; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; ISONIAZID; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TUBERCULOSIS; VIRAL LOAD;

EID: 34250822376     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328216f441     Document Type: Article

References (36)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-1021.
2. Corbett EL, Marston B, Churchyard GJ, DeCock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367:926-937.
3. Reid A, Scano F, Getahun H, Williams B, Dye C, Nunn P, et al. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect Dis 2006; 6:483-495.
4. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967; 95:935-943.
5. Ferebee SH, Mount FW, Murray FJ, Livesay VT. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis 1963; 88:161-175.
6. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337:801-808.
7. De Pinho AM, Santoro-Lopes G, Harrison LH, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS 2001; 15:2129-2135.
8. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, et al. Randomised trial of isoniazidversus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351:786-792.
9. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342:268-272.
10. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12:2447-2457.
11. Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Researcn on AIDS. N Engl J Med 1997; 337:315-320.
12. Johnson JL, Okwera A, Hom DL, Mayanja H, Mutuluuza K, Nsubuga P, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15:2137-2147.
13. Casado JL, Moreno S, Fortum J, Antela A, Quereda C, Navas E, et al. Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients. Clin Infect Dis 2002; 34:386-389.
14. Quigley MA, Mwinga A, Hosp M, Lisse I, Fuchs D, Porter JDH, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15:215-222.
15. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059-2064.
16. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34:543-546.
17. Jones JL, Hanson DL, Dworkin MS, DeCock KM. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis 2000; 4:1026-1031.
18. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-2116.
19. Girardi E, Sabin CA, D'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41:1772-1782.
20. Godfrey-Faussett P.World Health Organization/UNAIDS. Policy statement on preventive therapy against tuberculosis in people living with HIV, Report of a meeting held in Geneva 18-20 February 1998. Geneva, Switzerland, WHO 2003.
21. Getahun H, Van Gorkom J, Harries A, Harrington M, Nunn P, Perriens J, et al. Interim policy on collaborative TB/HIV activities. Geneva, Switzerland. Stop TB Department and Department of HIV/AIDS. World Health Organization 2004.
22. Okie S. Fighting HIV - lessons from Brazil. N Engl J Med 2006; 354:1977-1981.
23. AIDS epidemic update: December 2005. Special section on HIV prevention. Geneva, Switzerland. Joint United Nations Programme on HIV/AIDS and the World Health Organization Available at: http://www/unaids.org/epi/2005/doc/ EPIupdate2005_html_en/epi-05_00_en.htm Accessed: April 2007.
24. Moulton L, Golub JE, Durovni B. Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention. Clinical Trials: The Journal of the Society for Clinical Trials 2007; 4:190-199.
25. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr 1998; 17 (Suppl 1):S38-S41.
26. Castelo Filho A, Kritski AL, Barreto AW, Lemos ACM, Netto AR, Guimaraes CA, et al. II Brazilian consensus on treatment of tuberculosis - Brazilian guidelines for tuberculosis 2004 [in Portuguese]. J Bras Pneumol 2004; 30 (Suppl. 1):S62-S64.
27. World Health Organization. Global tuberculosis control: surveillance, planning, financing. Geneva, Switzerland: World Health Organzation 2006.
28. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358:1687-1693.
29. Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis 2001; 33:1762-1769.
30. Pulido F, Pena JM, Rubio R, Moreno S, Gonzalez J, Guijarro C, et al. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 1997; 157:227-232.
31. Nettles RE, Mazo D, Alwood K, Gachuhi R, Maltas G, Wendel K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38:731-736.
32. Churchyard GJ, Fielding K, Charalambous S, Day JH, Corbett EL, Hayes RJ, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS 2003; 17:2063-2070.
33. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD Jr, Pape JW. Effect of posttreatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000; 356:1470-1474.
34. Mosimaneotsile B, Talbot EA, Moeti TL, Hone NM, Moalosi G, Moffat HJ, et al. Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana. Lancet 2003; 362:1551-1552.
35. Day JH, Charalambous S, Fielding KL, Hayes RJ, Churchyard GJ, Grant AD. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 2006; 10:523-529.
36. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006; 12:744-751.